Mithra Pharmaceuticals financials
Mithra Pharmaceuticals
5493002FDD273HTEKK14 | Line item | 2022 | 2021 |
|---|---|---|
| Income statement | ||
| Revenue | €67.0M | €22.7M |
| Cost of sales | €19.6M | €15.7M |
| Gross profit | €47.4M | €6.9M |
| Other income | €7.2M | €4.8M |
| Operating profit (EBIT) | -€26.2M | -€87.9M |
| Finance costs | €23.4M | €13.1M |
| Profit before tax | -€11.5M | -€123.8M |
| Income tax expense | €48.1M | -€6.9M |
| Profit for the year | -€59.6M | -€116.9M |
| — attributable to owners | -€59.6M | -€116.9M |
| — attributable to NCI | €0 | €0 |
| Total comprehensive income | -€77.9M | -€134.2M |
| Per share | ||
| Basic EPS | €-1.22 | €-2.69 |
| Diluted EPS | €-1.22 | €-2.69 |
| Free cash flow / share | €-1.29 | €-2.03 |
| Cash flow statement | ||
| Net cash from operating activities | -€56.8M | -€76.8M |
| Income taxes paid | €322.0K | €0 |
| Net cash from investing activities | -€25.5M | -€54.7M |
| Purchase of PP&E (capex) | €6.4M | €11.5M |
| Purchase of intangibles | €19.3M | €9.7M |
| Net cash from financing activities | €77.9M | €25.6M |
| Lease liability payments | €6.7M | €7.2M |
| Balance sheet | ||
| Total assets | €442.4M | €421.9M |
| Non-current assets | €296.6M | €322.5M |
| Property, plant & equipment | €40.7M | €38.4M |
| Right-of-use assets | €65.5M | €69.3M |
| Intangible assets & goodwill | €5.2M | €5.2M |
| Current assets | €145.9M | €99.4M |
| Inventories | €50.3M | €43.9M |
| Trade & other receivables | €22.3M | €10.0M |
| Cash & equivalents | €28.3M | €32.9M |
| Total equity | €33.7M | €33.8M |
| Non-current liabilities | €278.3M | €292.3M |
| Long-term borrowings | €127.1M | €113.6M |
| Lease liabilities (non-current) | €38.3M | €42.4M |
| Current liabilities | €130.4M | €95.8M |
| Short-term borrowings | €46.0M | €45.3M |
| Lease liabilities (current) | €5.2M | €6.6M |
| Trade & other payables | €58.1M | €23.3M |
| Deferred tax liabilities | €4.4M | €6.1M |
| Derived metrics | ||
| Free cash flow | -€63.2M | -€88.3M |
| Operating margin | -39.2% | -387.7% |
| Net margin | -89.0% | -515.6% |
| Return on equity | -177.0% | -345.4% |
| Cash conversion ratio | 0.95× | 0.66× |
| Capex coverage | -8.94× | -6.69× |
| Other reported items | ||
| Additional Paidin Capital | €408.6M | €340.8M |
| Adjustments For Decrease Increase In Inventories | -€6.9M | -€8.5M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€7.2M | -€341.0K |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €11.9M | €10.4M |
| Adjustments For Increase Decrease In Trade and Other Payables | €18.2M | -€4.4M |
| Adjustments For Sharebased Payments | €2.0M | €1.1M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -€15.0M | -€79.3M |
| Comprehensive Income Attributable To Noncontrolling Interests | €0 | €0 |
| Comprehensive Income Attributable To Owners of Parent | -€77.9M | -€134.2M |
| Current Contract Assets | €45.0M | €12.5M |
| Current Derivative Financial Assets | €0 | €100.0K |
| Current Derivative Financial Liabilities | €2.6M | €1.9M |
| Current Government Grants | €1.4M | €1.6M |
| Deferred Tax Assets | €16.4M | €63.5M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€147.0K | €21.0K |
| Equity and Liabilities | €442.4M | €421.9M |
| Finance Income | €9.9M | €2.8M |
| Gains Losses On Financial Assets At Fair Value Through Profit Or Loss | €0 | -€6.4M |
| General and Administrative Expense | €14.7M | €12.5M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | -€2.6M | -€3.6M |
| Increase Decrease In Cash and Cash Equivalents | -€4.4M | -€105.8M |
| Increase Decrease Through Exercise of Options | €13.7M | — |
| Increase Decrease Through Sharebased Payment Transactions | €909.0K | €1.1M |
| Intangible Assets Other Than Goodwill | €134.9M | €105.0M |
| Interest Paid Classified As Financing Activities | €9.9M | €9.4M |
| Issue of Equity | €23.3M | €3.5M |
| Issued Capital | €41.2M | €32.3M |
| Noncurrent Contract Assets | €2.8M | €49.0K |
| Noncurrent Derivative Financial Liabilities | €15.3M | €2.9M |
| Noncurrent Financial Assets | €21.4M | €31.9M |
| Noncurrent Government Grants | €8.1M | €12.8M |
| Noncurrent Provisions | €266.0K | €266.0K |
| Other Comprehensive Income | -€18.3M | -€17.3M |
| Other Comprehensive Income Before Tax Cash Flow Hedges | -€10.4M | -€14.4M |
| Other Comprehensive Income Before Tax Gains Losses From Investments In Equity Instruments | -€10.5M | -€6.5M |
| Other Comprehensive Income Net of Tax Cash Flow Hedges | -€7.8M | -€10.8M |
| Other Comprehensive Income Net of Tax Gains Losses From Investments In Equity Instruments | -€10.5M | -€6.5M |
| Other Current Financial Liabilities | €16.0M | €15.8M |
| Other Noncurrent Assets | €9.5M | €9.3M |
| Other Noncurrent Financial Liabilities | €74.2M | €102.7M |
| Other Reserves | -€19.9M | -€2.5M |
| Proceeds From Government Grants Classified As Financing Activities | €154.0K | €41.0K |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €169.0K | €0 |
| Research and Development Expense | €64.0M | €85.2M |
| Retained Earnings | -€396.3M | -€336.6M |
| Selling Expense | €2.1M | €1.9M |
| Weighted Average Shares | 49.1M | 43.4M |
Every line item above is a fact tagged in Mithra Pharmaceuticals's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.